Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00950586 | Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702 | PHASE1 | COMPLETED | 48 | — | — | Aug 24, 2009 | Dec 24, 2009 | Jul 13, 2017 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | 14 days dosing |
| Cohort 2 | EXPERIMENTAL | Single dose followed by 14 days repeat dosing |
| Cohort 3 | EXPERIMENTAL | Up to 28 days repeat dosing with drug interaction |
| Name | Type | Description |
|---|---|---|
| GSK1043702 | DRUG | Oral dose in liquid or tablet formulation |
| Dextromethorphan | DRUG | 30mg Oral dose |
| Placebo | DRUG | To match GSK1034702 |
Inclusion Criteria: * Male or female of non childbearing potential * Generally healthy * Body mass index 19 - 29.9 kg/m2 (inclusive), body weight greater than or equal to 50 kg for males and greater than of equal to 45 kg for females * Normal Laboratory test results Exclusion Criteria: * Abuse of...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-101 |
| Eli Lilly and Company | LLY | 2 | — | Undisclosed |
| Rhythm Pharmaceuticals, Inc. | RYTM | 1 | — | Undisclosed |